Milestone events! DST DST successfully obtained FDA cGMP plant design project of a biochemical products co., ltd. in Guangzhou
Release time:
2024-10-25
Recently, DST and Guangzhou biochemical products Co., Ltd. signed a FDA cGMP plant design project cooperation agreement. This time, OTC products involving the enterprise need to be exported to the U.S. market. DST DST has helped a number of enterprises to complete the consulting and plant design services in the U.S. market.
Recently, DST and Guangzhou biochemical products Co., Ltd. signed a FDA cGMP plant design project cooperation agreement. This time, OTC products involving the enterprise need to be exported to the U.S. market. DST DST has helped a number of enterprises to complete the consulting and plant design services in the U.S. market.
This is the second FDA cGMP project cooperation between DST Durst and a biochemical product co., ltd. in Guangzhou. based on the good cooperation relationship in the past, the company once again chose DST Durst, which is professional, high-quality and efficient!
This cooperation project is DST DST according to enterprise requirements, the FDA cGMP workshop plant design and construction guidance. At the scene, the general manager of DST DST organized a team of consultants and design experts to visit the site, and conducted in-depth and comprehensive exchanges with the general manager of the company and the heads of various departments on the process flow, future capacity planning, automation planning, etc., to ensure compliance Under the premise of bringing a more optimized operation plan for the enterprise.
In recent years, DST Durst has focused on international GMP consulting work, including FDA, EU-GMP, TGA, PIC/S and other certification, audit, plant design, system construction and verification. Committed to helping enterprises to solve the quality system, verification implementation and other related needs, and in-depth study of the latest domestic and international regulations for verification requirements to help pharmaceutical companies build and improve the quality system.
Since the establishment of DST Durst, DST Durst has taken the mission of enabling more pharmaceutical enterprises to reach the international top quality management level, the concept of customer first, and its own specialty as its hard strength, focusing on serving international GMP consulting work, including FDA, EU-GMP, FDA, PIC/S, QP and other certification, auditing and verification work. It has successively provided international GMP services for Lizhu Pharmaceutical, Baiyunshan Pharmaceutical, China Resources Sanjiu, North China Pharmaceutical, Kangtai Biology, Baiji Biology, Longsha Biology, Sinopharm Zhongsheng and other enterprises, and has been recognized by customers. Has repeatedly used gap analysis, certification on-site counseling, simulation audit and other ways to help pharmaceutical companies through international certification audit and inspection, has helped Huiyu Pharmaceutical, China Resources Sanjiu, Sinopharm, Hanteng Bio, Raffles Pharmaceutical and other pharmaceutical companies through international certification audit and inspection. This is also the main reason why more and more customers choose DST DST. I believe that the service project with the enterprise will also be carried out smoothly. I wish the project a complete success in advance!
Key words:
Related Blog
Durst DST Regulation Group, noting that on July 1, 2024, the Drug Evaluation Center of the State Drug Administration (hereinafter referred to as CDE) issued a trial notice on the submission of electronic application materials for drug registration by network transmission. Starting from July 1, 2024, the trial work on the network transmission of electronic application materials for drug registration will be started, and applicants can submit electronic application materials for drug registration through network transmission. There is also an attachment: the reservation for network transmission of electronic declaration materials and the description of operation steps, which is convenient to guide everyone to submit electronic declaration materials.
2024-07-05
Recently, after the products of DST DST customers Sichuan well-known pharmaceutical companies passed PAI inspection in November 2023, they were officially approved in December. In June 2024, they officially sent several batches of products to enter the US market. This exciting news came at the time of the third FDA project audit of the client again. The customer is located in Neijiang City, Sichuan Province, an ancient city between Chengdu and Chongqing. The success of Huiyu Pharmaceutical has made this city more attractive to pharmaceutical people! Once again, congratulations to the customer products officially go to sea! The entry of products into the US market shows that DST customers have been strictly implementing quality management according to high standards, continuously optimizing production processes, and producing more high-quality products higher than national standards.
2024-07-05
Recently, after the products of DST DST customers Sichuan well-known pharmaceutical companies passed PAI inspection in November 2023, they were officially approved in December. In June 2024, they officially sent several batches of products to enter the US market. This exciting news came at the time of the third FDA project audit of the client again. The customer is located in Neijiang City, Sichuan Province, an ancient city between Chengdu and Chongqing. The success of Huiyu Pharmaceutical has made this city more attractive to pharmaceutical people! Once again, congratulations to the customer products officially go to sea! The entry of products into the US market shows that DST customers have been strictly implementing quality management according to high standards, continuously optimizing production processes, and producing more high-quality products higher than national standards.
2024-07-05
Argument! Hengrui Warning Letter, Is It FDA's Political Sanction?
Tieguai Liu saw many posts about whether there were political factors in Hengrui's warning letter. Today, Tieguai Liu will discuss this matter with everyone's concerns. First of all, we are very sensitive to see that the "first brother" of China's pharmaceutical industry has received a warning letter from the FDA of the United States. For today's Sino-US environment, we naturally think of the FDA's sanctions against the first brother due to the influence of US politics. It is completely understandable from everyone's interpretation. The following Tieguai Liu will discuss with you from both positive and negative dimensions:
2024-10-25
Durst DST continues to pay attention to the drug regulatory policies of countries around the world to help companies go to sea, and the following is the drug regulatory situation in Southeast Asian countries and regions.
2024-10-25